Your browser doesn't support javascript.
loading
Compared of efficacy and safety of high-dose donepezil vs standard-dose donepezil among elderly patients with Alzheimer's disease: a systematic review and meta-analysis.
Wang, Hecheng; Zong, Yu; Han, Yanshuo; Zhao, Jing; Liu, Hongqun; Liu, Yong.
Afiliação
  • Wang H; School of Life and Pharmaceutical Sciences, Dalian University of Technology, Panjin, Liao Ning, China.
  • Zong Y; School of Life and Pharmaceutical Sciences, Dalian University of Technology, Panjin, Liao Ning, China.
  • Han Y; School of Life and Pharmaceutical Sciences, Dalian University of Technology, Panjin, Liao Ning, China.
  • Zhao J; School of Life and Pharmaceutical Sciences, Dalian University of Technology, Panjin, Liao Ning, China.
  • Liu H; Medical School, Changchun Sci-Tech University, Changchun, Ji Lin, China.
  • Liu Y; School of Life and Pharmaceutical Sciences, Dalian University of Technology, Panjin, Liao Ning, China.
Expert Opin Drug Saf ; 21(3): 407-415, 2022 Mar.
Article em En | MEDLINE | ID: mdl-35099343
BACKGROUND: Donepezil is a first-line drug for the treatment of Alzheimer's disease (AD). However, there are no meta-analyses on efficacy and safety of high-dose versus standard-dose donepezil in the treatment of moderate-to-severe AD. RESEARCH DESIGN AND METHODS: We searched for randomized controlled trials (RCTs) from 1993 to May 2021 PubMed, Cochrane Library, EMBASE, Web of Science, and Scopus databases. The outcomes of the meta-analysis included cognitive function, global assessment, and the incidence of adverse events and serious adverse events. RESULTS: Five RCTs (2974 people) were included in this meta-analysis. The improvement of cognitive function was significant among the patients with the treatment of high-dose donepezil [SMD = 0.12, 95% CI: 0.03 ~ 0.22; p = 0.01]. Between the two groups, there was no significant difference in global assessment. Compared with standard-dose donepezil, there was no difference in the incidence of adverse events when high-dose donepezil was used. However, it was found that high-dose donepezil administration increased the risk of heart problems through subgroup analysis of the two serious adverse events. CONCLUSION: High-dose donepezil is more effective than standard-dose donepezil in improving cognitive function of the elderly with moderate-to-severe AD. However, more attention should be paid to patients with heart problems when high-dose donepezil was used.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Nootrópicos / Doença de Alzheimer Tipo de estudo: Clinical_trials / Systematic_reviews Limite: Aged / Humans Idioma: En Revista: Expert Opin Drug Saf Assunto da revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China País de publicação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Nootrópicos / Doença de Alzheimer Tipo de estudo: Clinical_trials / Systematic_reviews Limite: Aged / Humans Idioma: En Revista: Expert Opin Drug Saf Assunto da revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China País de publicação: Reino Unido